[1]
|
Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clini-cians, 73, 17-48. https://doi.org/10.3322/caac.21763
|
[2]
|
He, T., Cao, J., Xu, J., Lv, W. and Hu, J. (2020) Mini-mally Invasive Therapies for Early Stage Non-Small Cell Lung Cancer. Chinese Journal of Lung Cancer, 23, 479-486.
|
[3]
|
Lin, C., Liu, X., Zheng, B., Ke, R. and Tzeng, C.M. (2021) Liquid Biopsy, ctDNA Diagnosis through NGS. Life (Basel), 11, Article No. 890. https://doi.org/10.3390/life11090890
|
[4]
|
Chae, Y.K. and Oh, M.S. (2019) Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. Journal of Thoracic Oncology, 14, 16-24. https://doi.org/10.1016/j.jtho.2018.09.022
|
[5]
|
Papadopoulos, N. (2020) Patho-physiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. Recent Results in Cancer Research, 215, 163-180.
https://doi.org/10.1007/978-3-030-26439-0_9
|
[6]
|
Pai-Scherf, L., Blumenthal, G.M., Li, H., et al. (2017) FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist, 22, 1392-1399.
https://doi.org/10.1634/theoncologist.2017-0078
|
[7]
|
Tang, S., Qin, C., Hu, H., et al. (2022) Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells (Basel), 11, Article No. 320. https://doi.org/10.3390/cells11030320
|
[8]
|
Mandel, P. and Metais, P. (1948) Nuclear Acids in Human Blood Plasma. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales, 142, 241-243.
|
[9]
|
Horndalsveen, H., Alver, T.N., Dalsgaard, A.M., et al. (2023) Atezolizumab and Stereotactic Body Radiotherapy in Patients with Advanced Non-Small Cell Lung Cancer: Safety, Clinical Activity and ctDNA Responses—The ComIT-1 Trial. Molecular Oncology, 17, 487-498. https://doi.org/10.1002/1878-0261.13330
|
[10]
|
Pessoa, L.S., Heringer, M. and Ferrer, V.P. (2020) ctDNA as a Cancer Biomarker: A Broad Overview. Critical Reviews in Oncology/Hematology, 155, Article ID: 103109. https://doi.org/10.1016/j.critrevonc.2020.103109
|
[11]
|
Wu, N., Zhang, Z., Zhou, X., et al. (2020) Mutational Land-scape and Genetic Signatures of Cell-Free DNA in Tumour-Induced Osteomalacia. Journal of Cellular and Molecular Medicine, 24, 4931-4943.
https://doi.org/10.1111/jcmm.14991
|
[12]
|
Vu, P., Khagi, Y., Riviere, P., Goodman, A. and Kurzrock, R. (2020) Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients with Advanced Can-cers. JCO Precision Oncology, 4.
https://doi.org/10.1200/PO.19.00204
|
[13]
|
Lakhotia, R., Melani, C., Dunleavy, K., et al. (2022) Circulating Tumor DNA Predicts Therapeutic Outcome in Mantle Cell Lymphoma. Blood Advances, 6, 2667-2680. https://doi.org/10.1182/bloodadvances.2021006397
|
[14]
|
Slagter, A.E., Vollebergh, M.A., Caspers, I.A., et al. (2022) Prognostic Value of Tumor Markers and ctDNA in Patients with Resectable Gastric Cancer Receiving Periopera-tive Treatment: Results from the CRITICS Trial. Gastric Cancer, 25, 401-410. https://doi.org/10.1007/s10120-021-01258-6
|
[15]
|
Mencel, J., Slater, S., Cartwright, E. and Starling, N. (2022) The Role of ctDNA in Gastric Cancer. Cancers, 14, Article No. 5105. https://doi.org/10.3390/cancers14205105
|
[16]
|
Zhang, Z., Wu, H., Chong, W., Shang, L., Jing, C. and Li, L. (2022) Liquid Biopsy in Gastric Cancer: Predictive and Prognostic Biomarkers. Cell Death & Disease, 13, Article No. 903. https://doi.org/10.1038/s41419-022-05350-2
|
[17]
|
Hamakawa, T., Kukita, Y., Kurokawa, Y., et al. (2015) Moni-toring Gastric Cancer Progression with Circulating Tumour DNA. British Journal of Cancer, 112, 352-356. https://doi.org/10.1038/bjc.2014.609
|
[18]
|
Masfarre, L., Vidal, J., Fernandez-Rodriguez, C. and Montagut, C. (2021) ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC). Cancers, 13, Article No. 2869. https://doi.org/10.3390/cancers13122869
|
[19]
|
Osumi, H., Shinozaki, E., Yamaguchi, K. and Zembutsu, H. (2019) Clinical Utility of Circulating Tumor DNA for Colorectal Cancer. Cancer Science, 110, 1148-1155. https://doi.org/10.1111/cas.13972
|
[20]
|
Chakrabarti, S., Kasi, A.K., Parikh, A.R. and Mahipal, A. (2022) Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) As-sessment in Colorectal Cancer (CRC). Cancers, 14, Article No. 3078. https://doi.org/10.3390/cancers14133078
|
[21]
|
Sant, M., Bernat-Peguera, A., Felip, E. and Margeli, M. (2022) Role of ctDNA in Breast Cancer. Cancers, 14, Article No. 310. https://doi.org/10.3390/cancers14020310
|
[22]
|
Tzanikou, E. and Lianidou, E. (2020) The Potential of ctDNA Analysis in Breast Cancer. Critical Reviews in Clinical Laboratory Sciences, 57, 54-72. https://doi.org/10.1080/10408363.2019.1670615
|
[23]
|
Ma, F., Guan, Y., Yi, Z., et al. (2020) Assessing Tumor Heterogeneity Using ctDNA to Predict and Monitor Therapeutic Response in Metastatic Breast Cancer. International Journal of Cancer, 146, 1359-1368.
https://doi.org/10.1002/ijc.32536
|
[24]
|
Goldberg, S.B., Narayan, A., Kole, A.J., et al. (2018) Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clinical Cancer Research, 24, 1872-1880. https://doi.org/10.1158/1078-0432.CCR-17-1341
|
[25]
|
Lipson, E.J., Velculescu, V.E., Pritchard, T.S., et al. (2014) Circulating Tumor DNA Analysis as a Real-Time Method for Monitoring Tumor Burden in Melanoma Patients Under-going Treatment with Immune Checkpoint Blockade. The Journal for ImmunoTherapy of Cancer, 2, Article No. 42. https://doi.org/10.1186/s40425-014-0042-0
|
[26]
|
Singh, A.P., Cheng, H., Guo, X., Levy, B. and Halmos, B. (2017) Circulating Tumor DNA in Non-Small-Cell Lung Cancer: A Primer for the Clinician. JCO Precision Oncology, 1, 1-13. https://doi.org/10.1200/PO.17.00054
|
[27]
|
Li, L., Zhang, J., Jiang, X. and Li, Q. (2018) Promising Clinical Appli-cation of ctDNA in Evaluating Immunotherapy Efficacy. American Journal of Cancer Research, 8, 1947-1956.
|
[28]
|
Bergerot, P.G., Hahn, A.W., Bergerot, C.D., Jones, J. and Pal, S.K. (2018) The Role of Circulating Tumor DNA in Renal Cell Carcinoma. Current Treatment Options in Oncology, 19, Article No. 10.
https://doi.org/10.1007/s11864-018-0530-4
|
[29]
|
Garon, E.B., Rizvi, N.A., Hui, R., et al. (2015) Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 372, 2018-2028. https://doi.org/10.1056/NEJMoa1501824
|
[30]
|
Robert, C., Long, G.V., Brady, B., et al. (2015) Nivolumab in Pre-viously Untreated Melanoma without BRAF Mutation. The New England Journal of Medicine, 372, 320-330. https://doi.org/10.1056/NEJMoa1412082
|
[31]
|
Gouda, M.A., Huang, H.J., Piha-Paul, S.A., et al. (2022) Longitu-dinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precision On-cology, 6, e2100512.
https://doi.org/10.1200/PO.21.00512
|
[32]
|
van der Leest, P., Hiddinga, B., Miedema, A., et al. (2021) Circulating Tumor DNA as a Biomarker for Monitoring Early Treatment Responses of Patients with Advanced Lung Adenocarci-noma Receiving Immune Checkpoint Inhibitors. Molecular Oncology, 15, 2910-2922. https://doi.org/10.1002/1878-0261.13090
|
[33]
|
Bardelli, A. and Pantel, K. (2017) Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell, 31, 172-179.
https://doi.org/10.1016/j.ccell.2017.01.002
|
[34]
|
Nikanjam, M., Kato, S. and Kurzrock, R. (2022) Liquid Biopsy: Current Technology and Clinical Applications. Journal of Hematology Oncology, 15, Article No. 131. https://doi.org/10.1186/s13045-022-01351-y
|
[35]
|
Zhou, H., Zhu, L., Song, J., et al. (2022) Liquid Biopsy at the Frontier of Detection, Prognosis and Progression Monitoring in Colorectal Cancer. Molecular Cancer, 21, Article No. 86. https://doi.org/10.1186/s12943-022-01556-2
|
[36]
|
Spoor, J., Eyck, B.M., Atmodimedjo, P.N., et al. (2021) Liquid Biopsy in Esophageal Cancer: A Case Report of False-Positive Circulating Tumor DNA Detection Due to Clonal Hema-topoiesis. Annals of Translational Medicine, 9, Article No. 1264. https://doi.org/10.21037/atm-21-525
|
[37]
|
Salfer, B., Li, F., Wong, D. and Zhang, L. (2022) Urinary Cell-Free DNA in Liquid Biopsy and Cancer Management. Clinical Chemistry, 68, 1493-1501. https://doi.org/10.1093/clinchem/hvac122
|
[38]
|
Yu, H., Han, L., Yuan, J. and Sun, Y. (2020) Circulating Tumor Cell Free DNA from Plasma and Urine in the Clinical Management of Colorectal Cancer. Cancer Biomarkers, 27, 29-37. https://doi.org/10.3233/CBM-182344
|